Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall-Cell Lung Cancer?

• Main Authors: Angelina Cistaro, Natale Quartuccio, Alireza Mojtahedi, Piercarlo Fania, Pier Luigi Filosso, Mariapaola Cucinotta, Alfredo Campennì, Umberto Ficola, Sergio Baldari
• Format: Article
• Language: English
• Published: Hindawi Limited 2013-01-01
• Series: The Scientific World Journal
• Online Access: http://dx.doi.org/10.1155/2013/910957

Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2-year disease-free survival (2-year DFS)) of patients with advanced nonsmall-cell lung cancer (NSCLC). Materials and Methods. 86 stage III-IV NSCLC patients underwent 18 F-FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8±5.23, and the mean size of the primary lesion was 43.35 mm±16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7±8.05, and the mean size of the primary lesion was 41.6 mm±21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P=0.0235). Conclusions. In stage III-IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.